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Plasmodium falciparum malaria is one of the most significant causes of 
morbidity and mortality in tropical Africa. Chloroquine phosphate emerged as the 
revolutionary drug of choice for the prevention and treatment of malaria, pushing 
the previously administered quinine to the sidelines. However, since the 1970s, 
sensitivity to chloroquine has been on the decline. In response to this, health 
professionals began to turn to a different drug: artemisinin-based combination 
therapies (ACT). ACT is now accepted by the World Health Organisation (WHO) 
as the most effective strategy to treat Plasmodium falciparum malaria, despite some 
initial misgivings (their long-term usefulness has yet to be determined). In this light, 
based on a few tentative studies conducted since 2003, the WHO has established 
an emerging, yet noticeable, trend in growing resistance to ACT drugs. Although, at 
this moment, there is no hard evidence of any ACT resistance within the Ugandan 
population, this paper will explore, through published and unpublished sources, 
and a baseline survey conducted in July 2008 by AMREF (African Medical and 
Research Foundation, an international medical organisation based in Kenya), how 
this resistance will soon emerge in Uganda, what the precipitating factors are, and 
through a careful evaluation of these causes, offer courses of action so as avoid the 
devastating consequences of ACT resistance. 
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Plasmodium falciparum malaria is one of the most significant causes of 
morbidity and mortality in tropical Africa. The discovery of chloroquine phosphate 
was revolutionary for the prevention and treatment of malaria, pushing the 
previously administered quinine to the sidelines. It has been the drug of choice for 
several decades, thanks to its inhibition of parasite development in the blood. 
However, since the 1970s, sensitivity to the chloroquine has been on the decline, and 
resistance to anti-malaria drugs is now proving a major and challenging problem in 
most affected parts of the world. This emergence of chloroquine resistance has been 
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associated with recent surges in malaria mortality in several regions of the world; in 
fact, now, almost every malaria-susceptible country is reporting partial to full 
chloroquine resistance, with huge implications for its susceptible populace (World 
Hwalth Organization (WHO), 2006).  
In response to this, health professionals began to turn to a different drug: 
artemisinin-based combination therapies (ACT). The World Health Organisation 
(WHO) now recommends ACT as the most effective strategy to treat Plasmodium 
falciparum malaria, despite some initial misgivings (their long-term usefulness has yet 
to be determined). In this light, based on a few tentative studies conducted since 
2003, the WHO has established an emerging, yet noticeable, trend in growing 
resistance to ACT drugs. This worrying claim could have many implications for the 
vulnerable population in tropical Africa, and Uganda specifically, where the incidence 
remains high, the infrastructure lacking, and the manpower small. Although, at this 
moment, there is no hard evidence of any ACT resistance within the Ugandan 
population, this paper will explore, through published and unpublished sources, and 
a baseline survey conducted in July 2008 by AMREF (African Medical and Research 
Foundation, an international medical organisation based in Kenya), how this 
resistance will soon emerge in Uganda, what the precipitating factors are, and 
through a careful evaluation of these causes, offer courses of action so as avoid the 
devastating consequences of ACT resistance. First, I will offer background on ACT 
and its extensive use; then, I shall outline the Ugandan malarial profile, considering 
the burden of disease, the particularities of resource management and cultural climate 
that would foster the emergence of antibiotic resistance. Finally, I will discuss how 
state efforts to educate the population are fruitless in the face of a crippled 
infrastructure, and argue for health sector refurbishment and re-equipment as 




Plasmodium falciparum malaria is one of the most significant causes of 
morbidity and mortality in tropical Africa. The WHO estimates that the parasite is 
responsible for 1.4-2.6 million deaths per annum, as well as 270-480 million clinical 
attacks. Chloroquine-resistant strains of P. falciparum were first observed in 1978 in 
East Africa and, within 10 years, similar strains had been reported in all tropical 
African countries, resistant to chloroquine, sulfadoxine-pyrimethamine and 
amodiaquine (conventional antimalarial drugs), amongst others. In response to this 
resistance and the health threats it entails, artemisinin-based combination therapies 
(ACT, derived from the plant Artemisia annua – sweet wormwood) were deployed on 
a large scale, after being strongly recommended by the WHO, and are gradually 
replacing obsolete drugs in malaria-resistant areas. To the medical and public health 
world, these compounds appear to be the wonder-drugs: they are well tolerated by 
patients, and could cure falciparum malaria in 3-7 days by reducing gametocyte 
carriage, thus diminishing malaria transmission. The WHO estimated that 120 
million ACT treatments would be needed globally annually. It is so far, undoubtedly, 
the most effective and modern drug approved by FDA and on market (WHO, 2006). 
The possibility of ACT resistant strains of P. falciparum would have 
devastating consequences for millions of lives in dozens of countries. Establishing 
158 Consilience 
 
whether this is a potential outcome is of crucial importance to the medical and public 
health world. There has been some research into the matter, the most noteworthy of 
which was conducted by the WHO in 2007. They hoped to ascertain whether there 
is prevalence of ACT resistance, or strong indicators to the prospect of it, by 
conducting a clinical trial in the Thai-Cambodian border region. Its results showed 
that there is a noticeable trend, albeit in its very beginnings, and that this possibility 
will become reality (WHO: Report Of A Meeting On Containment Of Artemisinin Tolerance, 
2008). 
This paper will spotlight the risk of emerging artemisinin resistance in 
Uganda, a tropical sub-Saharan country that experiences intense perennial malaria 
transmission over 95% of the landmass, and where it accounts for 39-44% of 
outpatient presence, and 20% of inpatient mortality (AMREF-Uganda: Malaria, 
AIDS and TB (MAT) Integrated Model Baseline Study, 2008). The Ugandan 
Ministry of Health estimates that malaria causes between 70,000 and 100,000 
fatalities per annum, the majority of which are children. The indirect and direct costs 
of malaria are high, as poor households spend an estimated 25% of their monthly 
income on malaria-related care (Ministry of Health, Uganda, 2003). Although 
Uganda has developed a policy for integrated malaria, HIV/AIDS and TB 
management, it is poorly implemented, exacerbated by several budgetary limitations, 
inadequate infrastructure and equipment and a healthcare workforce crisis. The 
Ugandan districts of Luwero and Kiboga, which this paper will focus on, have been 
part of the country‟s disease management initiatives, but with slow progress: the 
massive nation-wide campaigns for Insecticide Treated Nets (ITNs) and Intermittent 
Preventative Treatment in pregnancy (IPTp) have yielded low results; 54% of 
pregnant women currently receive the recommended 2 doses of Sp/Fansidar for 
IPTp, whilst the national target is 80%; finally, only 62% of symptomatic children 
under 5 years old access the antimalaria treatment they need within 24 hours of 
fever, and instead rely first on home-based care of fever (MAT Baseline Study, 2008).  
Despite the WHO carrying out their study on the Thai-Cambodian border, I 
deem the examination of ACT resistance in Uganda to be a relevant course of action. 
It should be noted that both regions have experienced significant population 
movements, a risk factor for the spread of malaria resistance: approximately 200 000 
people cross from Cambodia into Thailand on average per annum, and in Uganda, 
civil conflict forced 2 million people into Internally Displaced Persons, or IDP, 
camps – 1 million have returned home since. In terms of demographics, Uganda has 
less successful statistics on most levels than both Cambodia and Thailand (life 
expectancy, under-5 mortality, GNI/capita, ITN use, etc.) – if Uganda is at a 
relatively less developed stage than the other 2 countries, with a much faster growing 
population (Uganda‟s fertility rate is 6.6, whereas Thailand and Cambodia are at 1.8 
and 3.3, respectively (UNICEF, 2006)), the need to study ACT resistance is Uganda 
is just as valid and pressing, because of its rapidly expanding population. 
In Uganda, the landmass is divided into 80 districts; each district is 
progressively divided into sub-districts, counties, sub-counties, parishes and villages. 
There are typically 1-4 villages per parish. Health centres are graded as Health 
Centres II, III IV, with each being more equipped than the last; each serves a parish, 
a sub-county and a sub-district, in that order (Special Programme For Research And 
Training In Tropical Diseases, 2006). 
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3. Status Quo in Luwero and Kiboga 
 
A baseline survey conducted by AMREF-Uganda in June/July 2008 sought 
to establish awareness, treatment practices and behaviour patterns associated with 
malaria of local Ugandans living in the districts of Luwero and Kiboga. The research 
team compiled a table of results, the most pertinent of which are listed here: 
 
HOUSEHOLD KNOWLEDGE, ATTITUDE AND PRACTICE  
KAP Kiboga Luwero MEAN 
Nº of ITNs in household 0.9
2 
1.1 1.01 
% ITNs in good condition 56 66 61 




% recognise ITNs as best protection 95 98.6 97 
% of population without ITNs 54 56 55 
% knowledge of mosquitoes as vector of malaria 96 83 90 
% knowledge of breeding grounds for mosquitoes 82 91 87 
% knowledge of destruction of mosquitoes 69 71 70 
% awareness of IRS (Indoor Residual Spraying) 78 92 85 
% favouring IRS 88 45 67 
% against IRS 3 34 19 
% recognised fever as symptom of child malaria 90 97 94 
% initially try home-based treatments 76 50 63 
% take child to HC within 6 hrs 69 65 67 
% know of IPTp 73 67 70 
% with VHT in community 74 45 60 
% seek treatment from VHT 74 -  
All values quoted from now on will be the mean values, unless indicated as Luwero- or 
Kiboga-specific results 
 










% diagnoses done 
symptomatically 
100 82 n/a 66 
% units able to offer ACT 69 67 100 Yes  
% units able to offer ITNs 0 17 0 No 
% units able to test by 
blood slide 
0 25 n/a 34 
Number of pregnant 
women on IPTp 











% diagnoses done 
symptomatically 
94 58 69 
% units able to offer ACT 81 100 100 
% units able to offer ITNs 0 0 67 
% units able to test by 
blood slide 
12.5 93 100 
Number of pregnant 
women on IPTp 
6 16 85 
* There is no hospital in Luwero – Health Centre IV is the most equipped 
facility of the district 
 
KIBOGA and LUWERO (averaged) – STAFF AND EQUIPMENT: 








% actual staff of authorised 37 48 58 51 
Ratio patients : medical 
workers 
206:1 96:1 65:1 41:1 
Presence of lab Not 
required 
68% 100% Yes 
% actual lab staff of 
authorised 
n/a 39 73 60 
Presence of binocular 
microscope 
n/a 57% 100% Yes 






The most sustainable way to treat and cure malaria is to educate the 
populations at risk about protection from the parasite: that is, how to avoid infection 
altogether. This can be done through the use of Insecticide Treated Nets (ITNs), 
Indoor Residual Spraying (IRS) of huts, and finding other ways of avoiding or 
destroying mosquitoes, the vector of P. falciparum. Therefore, the most pressing 
questions are those relating to the vector: breeding, habits, avoidance. 
However, the immediate reaction to these results is the irregularity between 
awareness of vector and awareness of its habits: 90% of the participants were aware 
that mosquitoes were the vector for malaria, but much fewer knew their breeding 
grounds, and, therefore, how to prevent their propagation or how to destroy them.  
ITN usage, a world-recognized method of prevention against malaria, did not 
receive strong results. Although respondents were very much aware of its advantages 
(97% assert it gives the best protection1), the availability and quality of the nets is 
very limited. Each household has on average 1 net, with an average ratio of one net 
to 6 persons. Because of their higher vulnerability, it is the children who are usually 
put under the net at night; this still leaves a large group of individuals who remain 
exposed. Approximately one third of nets are in poor condition, and therefore less 
efficacious. Finally, around half of the population do not own a net in the first place, 
                                                 
1 All values quoted hereafter are directly from the table of results from the MAT Baseline Study, 
unless specified. 
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which is contrary to government policies of complete net coverage and usage. This 
remains despite the Ministry of Health‟s target to increase the proportion of 
household with one or more nets from 13% to 75% by the year 2005. According to 
the health centre survey, very few clinics are even able to provide the ITNs as 
required by the Ministry of Health. These are to be subsidised unless in an 
emergency situation (e.g. refugee or IDP camps), made affordable to all who need 
them (Zurovac, 2008).  
Survey responses to the preferred and practiced course of action in reaction 
to visible infection remain varied. Although 94% recognise that fever is a symptom 
of the parasite, 63% still opt for home-based remedies before seeking immediate 
clinical attention. This delay is not in the best interest of the patient, and could be 
due to several factors, among them: wariness of Western antibiotics and trust in 
traditional practices, distance or inaccessibility to health centres, or inability of health 
centre to cater to the needs of the populace (MAT Baseline Study, 2008). By law, 
level II health centres are not required to have a working laboratory, but level III 
centres are. Laboratories are needed to conduct blood slide tests. The survey shows 
that although some clinics claim to be able to test by blood slide (i.e. have a 
laboratory), they still do the majority of their diagnoses symptomatically. This is due 
to poor infrastructure, lack of equipment, lack of personnel, and lack of electricity. 
Every laboratory should have a binocular microscope for blood slide testing, and 
many still don‟t (57% of level III centres), and continue to use the obsolete 
monocular microscope. Furthermore, the lack of full personnel puts a huge strain on 
all functions of the health clinic. With 37% to 58% of the required staff manning the 
clinics, services are completed far less efficiently than they could be. The most 
common reason for this lack of staff is that they are not compensated for their 
services: salaries are rarely paid on time, if at all, and staff quarters are poorly 
maintained, if present at all. With the average number of patients to health worker 
ratio ranging from 41 to 206 per worker, the staff does not have the time to conduct 
all the necessary tests, regardless of the availability of resources.  
Village Health Teams (VHTs) are a national public health initiative that have 
been gradually implemented all over the African continent over the last few decades. 
They consist of several individuals, often volunteers, who are trained to diagnose 
illnesses by their symptoms, and recommend the best course of action to the patient. 
This can mean administering basic treatments and medications, such as ACT. This is 
especially useful for villages where the health centres are hard to access. 
Unfortunately, VHTs have some shortcomings: there is often a lack of trained, 
voluntary personnel, meaning that many targets have not been met. There have also 
been reports of mismanagement: drug misappropriation, or some other forms of 
mismanagement. Furthermore, as their resources are limited, and because symptoms 
can differ from patient to patient, illnesses are sometimes diagnosed and drugs 
prescribed inappropriately. However, according to the results, 60% of the 
respondents report a VHT in their village, and in Kiboga, 74% would seek medical 
help from them, demonstrating their promising status within the community. 
All of these results point to a populace that relies more on treatment than 
prevention of malaria, despite national efforts to curb this unsustainable trend. With 
ineffectual testing methods and obsolete equipment, staffed by a fraction of the 
required personnel, Ugandans boast little in the way of early detection systems, 
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which would indicate a deep, and dangerous, reliance on pharmaceutical recourses, 
now in the form of ACT. 
A study conducted in 2008 investigated the effectiveness of ACT in three 
sub-Saharan countries, including Uganda. The researchers reported that the 
adherence to treatment was 81%, lower than the two other trials in Nigeria and 
Ghana (Ajayi, 2008). The study did not offer suggestions as to why this was the case. 
Firstly, in this study, unavailability of medications is not one of the factors, as these 
were provided by the researchers. The other options for this incomplete adherence 
could be negligence, or the personal judgement of the patients. In other words, 
participants might have feared that once the clinical trial was over, they would no 
longer be able to access medication regularly because of inadequate local medical 
infrastructure. There is some likelihood that patients personally allotted some of the 
medication to treat their current infection until they felt better, and then kept the rest 
for the next times they should fall ill (Colonel Robert Leitch, 2008). This means they 
took an incomplete course of antibiotic treatment, a crucial factor in developing drug 
resistance. 
 
4. How Can We Solve These Problems? 
 
The Centre for Disease Control (CDC) outlines three principal ways to avoid 
antibiotic resistance:  
1. only prescribe antibiotic therapy when likely to be beneficial to the 
patient 
2. use an agent targeting the likely pathogens 
3. use the antibiotic for the appropriate dose and duration (Center For 
Disease Control (CDC), 2008) 
Given these guidelines, we can formulate courses of action pertinent to each 
precipitating factor, each appropriate and feasible given Ugandan circumstances. 
First and foremost, given the poor knowledge about vector habits, education 
about malaria needs to be consolidated to help avoid contracting the disease 
altogether. The burden of disease could be significantly reduced if more locals knew 
to empty out old water containers, drain or pour out sources of stagnant water or 
cover small puddles with vegetable oil, so that the mosquito larvae cannot emerge – 
this would lead to a decrease in mosquito populations around the homes.  
Although most (85%) were aware of IRS, a large proportion (19%) were 
against the incentive.  This programme has been proven to be highly effective against 
malaria, and although its coverage its presence is patchy across Africa, full coverage 
would lower the frequency of malaria cases (Malaria Consortium, 2008). 
The biggest shortcoming revolving around educational initiatives about ITNs 
is that, all too often, the health clinics, responsible for providing them, cannot. 
According to the survey conducted by AMREF-Uganda, a scarce handful of health 
centres are stocked with ITNs; in Kiboga, even the main district hospital is out of 
stock. Consequently, the only recourse for the population is to purchase nets, which 
are not always within their means, or go without and risk malaria infection. This can 
only end negatively: if one is told over and over that seatbelts are the only way to be 
protected in a car, and then no car is equipped with that feature, the at-risk 
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population will be frustrated and angry. Analogously, the effects of educating locals 
about the marvels of an ITN are lost when failing to equip them with one. 
I propose that this be incorporated more fully into Ugandan National Health 
Policy, and that they be made completely free of charge. They should be distributed 
in schools, churches, clinics, police stations and post offices, and be made a 
mandatory parting gift for every new mother when she leaves the clinic, should she 
deliver there. Every Traditional Birth Attendant (TBA) should have a stockpile to 
hand out to mothers with newborns as well. Each time they should be accompanied 
with an explanation as to proper use: the sleeping person should be entirely covered, 
frayed nets or those with holes are not useful, etc. Since the introduction of ITN in 
the country in the early 1990s, the promotion of their use has been mainly by NGOs 
in the form of limited projects covering small populations. This should be expanded 
to the whole country, enough for every person. 
A significant factor in precipitating ACT resistance is the fact that it can be 
administered inappropriately, as 83% of patients in Kiboga, and 74% in Luwero are 
diagnosed symptomatically, i.e. without undergoing a blood slide test, and treated 
through the judgement of the health workers. Clinics need to have the proper 
infrastructure. If level III clinics were updated to have full working labs, with 
modern equipment and full staff, the situation would be ideal. But, on a more 
realistic scale, the introduction of Rapid Diagnostic Tests (RDTs) would alleviate the 
burden of work substantially. In the face of the ongoing malaria crisis, limiting ACTs 
to individuals who are confirmed to be carrying infectious malaria parasites becomes 
extremely important, especially in the context of rising medication costs and drug 
resistance. RDTs are lateral flow 'immuno-chromatographic' antigen-detection tests, 
which rely on the capture of dye-labeled antibodies to produce a visible band on a 
strip of nitro-cellulose – in other words, a malaria “prick-test”. These tests are more 
cost-effective ($0.95 each) than prescribing an antimalaria treatment (between $0.90 
and $2.40 for an artemether-lumefantrine treatment). There are still some issues 
surrounding shelf-life, price and the training required to administer it. The WHO 
estimates that for the most cost-effective and successful RDT campaign each test 
should be priced at $0.65 (WHO Malaria Rapid Diagnostic Tests, 2008). This is still 
in the works, but could alleviate the burden of disease greatly and drastically reduce 
the rate at which antibiotic resistance grows, as only infectious malaria sufferers 
would be treated with ACT. Ingesting ACT when one should not be, regardless of 
the possible physical side-effects, is a huge causative agent of drug resistance; it goes 
against all three of the guidelines stated by the CDC. Malaria symptoms can be 
confused with those of another ailment, just as a health worker, without running the 
proper tests, could misdiagnose malaria as flu or food poisoning, and not administer 
antibiotics when needed.  
Lack of adherence to ACT is a significant problem, where patient do not 
complete the full treatment as prescribed. One reason for this, which happens in 
every culture, is that once a patient begins to feel better, they will stop taking the 
medication, due to forgetfulness or personal judgement. This is a serious problem in 
all medical settings in creating drug resistance, and needs to be clearly outlined to 
every single patient who is given antibiotics. Another reason is that the patient does 
not necessarily always understand the requirements and stipulations to complete the 
treatment. In a study by Zurovac et al. (2008), they stated that they  
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“found that nearly all patients left the facility with an explanation on dosing 
schedule; however, administration of the first AL (artemether-lumefantrine) dose, 
and provision of advice to take AL after the meal and what to do in case of vomiting 
was rarely performed across all age groups. Despite Uganda's investment in 
interventions to improve the quality of care such as IMCI (Integrated Management 
of Childhood Illness), deficiencies in drug dispensing and counseling practices 
persist. The reasons for these suboptimal practices are not clear and demand further 
qualitative research including health workers misperceptions on administration of 
first AL dose in the absence of food, the effects of lack of potable water on 
administering drugs at peripheral facilities and the effects of AL blister packages on 
the provision of replacement dose in case of vomiting. Better understanding of these 
factors should guide further interventional studies to improve dispensing and 
counseling practices as an integral part of appropriate prescribing” (Zurovac, 2008). 
Another possible reason for disobedience to the treatment regime, more 
specific to developing countries, is the fear that next time they fall ill, there will not 
be any medication available. This is not an unreasonable assumption, given that in 
Kiboga, 31% of level II health clinics were unable to provide ACT. Some patients 
decide to keep a small stash for when they or a loved one becomes ill and self-
medicate (Colonel Robert Leitch, 2008). This is dangerous and unhealthy, because it 
means that they do not finish their own course of treatment. And although 81% 
adherence is high, it should consistently be as close to 100% as possible. To achieve 
this, ACT must be deployed regularly to all clinics, and perhaps other community 
health workers, such as Traditional Birth Attendants, who could also be equipped 
with RDTs and IPTp when expectant mothers come for „check-ups‟. This could 
potentially also lower rates of malaria during pregnancy, which is immensely 
dangerous for both mother and baby. Perhaps implementing a system similar to 
Directly Observed Therapy Short-Course for tuberculosis, where someone checks 
on the patient every day to ensure they are taking their medication consistently, 
would be beneficial. But malaria cases are more frequent than TB, so this could 
prove to be inefficient; it should still be considered though.  
Another acute problem is the insufficient production of ACT, and thus the 
relatively high price of the treatment. The cultivation of Artemisia annua, from which 
artemisinin is derived, was up until recently confined to China and Vietnam. The 
WHO has undertaken campaigns to stimulate cultivation in Kenya and the United 
Republic of Tanzania, and I suggest this policy be expanded to Uganda, as well as 
other parts of Africa. This would add to the Ugandan economy, help African farmers 
contribute more significantly to the world market, and be one more step in turning 
away from foreign aid to a more self-sustaining health policy ( 
WHO: Meeting on the production of artemisinin and artemisinin-based combination therapies, 6-7th June 
2005, Arusha, United Republic of Tanzania, Global Malaria Programme, 
WHO/HTM/MAL/2006.1113. 
Finally, post-treatment testing to check the efficacy of ACT treatment, and 
full recovery is important to avoid recurrence and drug resistance; this could be done 
through another RDT, to confirm that all parasites are dead, and therefore none 
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5. Obstacles Ahead 
 
Many of the initiatives suggested to combat mounting antibiotic resistance do 
not account for the shortcomings of the public health policy structure in Uganda. 
There is widespread corruption and inefficiency in government. In fact, its Ministry 
of Health is notorious throughout the country for having its parking lot jammed with 
large, new Land Cruisers, belonging to the employees. Making the system more 
transparent and equitable, rather than letting funds trickle down unmonitored, could 
help solve the problem.  Alternatively the installation of internationally approved 
financial watchdogs to ensure that the funds are routed appropriately would also be 
effective. This issue needs to be seriously tackled by the Ugandan authorities. 
Another growing problem in Uganda is the health workforce crisis. During a 
conversation I had a with a 25 year old surgeon in Luwero, who had been running 
the level IV clinic and performing surgery by himself for 5 years, he expressed his 
desire to relocate to the UK, or Germany, for the promise of a better salary. A 
medical student who was present also told me she hoped to move abroad after she 
completed her studies. Health staff are rarely paid on time, if at all, and their salaries 
are pitiful, even in the Ugandan context. Some of the rural health workers have been 
reported to hoard medication themselves. Indeed, the level II centre in Bulaga, 
Kiboga, had to be closed due to drug misappropriation. In another clinic, the doctor 
was charging $2-5 for HIV testing, and pocketing the profits (MAT Baseline Study, 
2008). Often this is not out of malice, but desperation. This needs to be remedied 
immediately so that the Ugandan people do not lose their brightest and most able 
medical minds to foreign countries in their time of need. 
The surest way to avoid drug resistance is, quite simply, to lower the burden 
of disease. However, the first recourse to noticeable antibiotic resistance, like in the 
cases of quinine and chloroquine, should not be to market a newer drug – this will 
not automatically lower the incidence and prevalence of malaria. There is no such 
thing as a successful „silver bullet‟ approach. The sheer volume of malaria sufferers 
will trump whatever efforts are put into drug adherence, RDT campaigns or drug 




The biggest challenges facing the medical and public health community, in 
avoiding ACT resistance, is the lack of substantial success in lowering malaria 
incidence and prevalence. The burden of malaria is deleterious within Ugandan 
society, abetted by the scarcity of health care personnel and mishandling of health 
resources. The paltry governmental successes do not account for long-term 
implications of pharmaceutical mismanagement: Uganda‟s government and the 
WHO cannot just keep adapting medication if there is no attempt to change 
behavioural patterns and vector spread. Resistance to an antibiotic is a natural 
biological phenomenon that happens inevitably when exposed to the drug – it is only 
a matter of time. Yet, more importantly, it is useless to spend so much time, effort 
and money on education and raising awareness if we cannot provide the medical 
supplies, such as ITNs and the medication itself, to tackle the very problems we are 
deliberately highlighting to the populace. In other words, what is the point of 
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educating a Ugandan family about correct ITN usage if we then cannot provide them 
with one? Refurbishment of laboratories and health clinics, re-equipment with 
modern tools and medications regularly, and personnel training with constant 
appropriate compensation must come first. Education about vector transmission, 
ITNs or IPTP treatment should come once the infrastructure is ready to cope with 
this new knowledge. However, many obstacles lay within this commitment to 
refurbish the health system, notably in the distribution of funds within the Ministry 
of Health – whilst the necessity for transparency and efficiency are unquestionable, 
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Appendix 
 
Figure 1: Map of Kiboga District, Uganda. 
 








































   
Figure 3: A rural health centre level II (consulting room + store; current staffing 
level: 1 health worker). 
 
   
Figure 4: A health centre level III (laboratory, ANC/OB + integrated HIV care) 
 
 
Figure 5: Patient beds in level III facility 
Consilience Siegel: ACT Resistance 
 
Figure 6: Monocular microscope (best suited to a 6th form Biology class – not 
powerful enough to carry out necessary analyses) 
Figure 7: Binocular microscope donated by AMREF 
 
 
                        
Figure 8: Empty solar-powered blood bank. 
Figure 9: Solar power for blood bank. 
 
 




                
Figure 11: Expired Drugs waiting [months] for collection . 




Figure 13: The [only] midwife leaves a Health Center III for a day of immunization 
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